LAB Revenue Breakdown
LAB Revenue Breakdown summary
STANDARD BIOTOOLS INC. (LAB). Quarter ended 2026-06-30 · 10-Q · every retained filed quarter remains available.
- 2025-12-31: Others Not split by product in the filing$85.33M100.00%; Total revenue $85.33M.
- 2024-12-31: Others Not split by product in the filing$91.01M100.00%; Total revenue $91.01M.
- 2023-12-31: Others Not split by product in the filing$106.34M100.00%; Total revenue $106.34M.
- 2022-12-31: Others Not split by product in the filing$97.95M100.00%; Total revenue $97.95M.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $85.33M 100.00% | $85.33M |
| 2024-12-31 | Not split by product in the filing $91.01M 100.00% | $91.01M |
| 2023-12-31 | Not split by product in the filing $106.34M 100.00% | $106.34M |
| 2022-12-31 | Not split by product in the filing $97.95M 100.00% | $97.95M |
| 2021-12-31 | Not split by product in the filing $130.58M 100.00% | $130.58M |
| 2020-12-31 | Not split by product in the filing $138.14M 100.00% | $138.14M |
| 2019-12-31 | Not split by product in the filing $117.24M 100.00% | $117.24M |
| 2018-12-31 | Not split by product in the filing $112.96M 100.00% | $112.96M |
| 2017-12-31 | Not split by product in the filing $101.94M 100.00% | $101.94M |
| 2016-12-31 | Not split by product in the filing $104.45M 100.00% | $104.45M |
| 2015-12-31 | Not split by product in the filing $114.71M 100.00% | $114.71M |
| 2014-12-31 | Not split by product in the filing $116.46M 100.00% | $116.46M |
| 2013-12-31 | Not split by product in the filing $71.18M 100.00% | $71.18M |
| 2012-12-31 | Not split by product in the filing $52.33M 100.00% | $52.33M |
| 2011-12-31 | Not split by product in the filing $42.87M 100.00% | $42.87M |
| 2010-12-31 | Not split by product in the filing $33.56M 100.00% | $33.56M |
| 2009-12-31 | Not split by product in the filing $25.41M 100.00% | $25.41M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $20.10M 100.00% | $20.10M |
| 2026-03-31 | Not split by product $21.15M 100.00% | $21.15M |
| 2025-12-31 | Not split by product $23.80M 100.00% | $23.80M |
| 2025-09-30 | Not split by product $19.55M 100.00% | $19.55M |
| 2025-06-30 | Not split by product $21.76M 100.00% | $21.76M |
| 2025-03-31 | Not split by product $20.22M 100.00% | $20.22M |
| 2024-12-31 | Not split by product $24.78M 100.00% | $24.78M |
| 2024-09-30 | Not split by product $22.09M 100.00% | $22.09M |
| 2024-06-30 | Not split by product $22.49M 100.00% | $22.49M |
| 2024-03-31 | Not split by product $45.54M 100.00% | $45.54M |
| 2023-12-31 | Not split by product $28.19M 100.00% | $28.19M |
| 2023-09-30 | Not split by product $25.37M 100.00% | $25.37M |
| 2023-06-30 | Not split by product $27.67M 100.00% | $27.67M |
| 2023-03-31 | Not split by product $25.12M 100.00% | $25.12M |
| 2022-12-31 | Not split by product $27.02M 100.00% | $27.02M |
| 2022-09-30 | Not split by product $25.65M 100.00% | $25.65M |
| 2022-06-30 | Not split by product $18.78M 100.00% | $18.78M |
| 2022-03-31 | Not split by product $26.50M 100.00% | $26.50M |
| 2021-12-31 | Not split by product $38.27M 100.00% | $38.27M |
| 2021-09-30 | Not split by product $28.50M 100.00% | $28.50M |
| 2021-06-30 | Not split by product $31.02M 100.00% | $31.02M |
| 2021-03-31 | Not split by product $32.79M 100.00% | $32.79M |
| 2020-12-31 | Not split by product $44.61M 100.00% | $44.61M |
| 2020-09-30 | Not split by product $39.86M 100.00% | $39.86M |
| 2020-06-30 | Not split by product $26.06M 100.00% | $26.06M |
| 2020-03-31 | Not split by product $27.62M 100.00% | $27.62M |
| 2019-12-31 | Not split by product $32.44M 100.00% | $32.44M |
| 2019-09-30 | Not split by product $26.50M 100.00% | $26.50M |
| 2019-06-30 | Not split by product $28.20M 100.00% | $28.20M |
| 2019-03-31 | Not split by product $30.11M 100.00% | $30.11M |
| 2018-12-31 | Not split by product $32.33M 100.00% | $32.33M |
| 2018-09-30 | Not split by product $28.96M 100.00% | $28.96M |
| 2018-06-30 | Not split by product $26.43M 100.00% | $26.43M |
| 2018-03-31 | Not split by product $25.25M 100.00% | $25.25M |
| 2017-12-31 | Not split by product $27.75M 100.00% | $27.75M |
| 2017-09-30 | Not split by product $24.75M 100.00% | $24.75M |
| 2017-06-30 | Not split by product $23.91M 100.00% | $23.91M |
| 2017-03-31 | Not split by product $25.53M 100.00% | $25.53M |
| 2016-12-31 | Not split by product $25.08M 100.00% | $25.08M |
| 2016-09-30 | Not split by product $22.19M 100.00% | $22.19M |
| 2016-06-30 | Not split by product $28.17M 100.00% | $28.17M |
| 2016-03-31 | Not split by product $29.00M 100.00% | $29.00M |
| 2015-12-31 | Not split by product $30.72M 100.00% | $30.72M |
| 2015-09-30 | Not split by product $28.64M 100.00% | $28.64M |
| 2015-06-30 | Not split by product $28.62M 100.00% | $28.62M |
| 2015-03-31 | Not split by product $26.73M 100.00% | $26.73M |
| 2014-12-31 | Not split by product $33.49M 100.00% | $33.49M |
| 2014-09-30 | Not split by product $29.64M 100.00% | $29.64M |
| 2014-06-30 | Not split by product $27.61M 100.00% | $27.61M |
| 2014-03-31 | Not split by product $25.72M 100.00% | $25.72M |
| 2013-12-31 | Not split by product $20.88M 100.00% | $20.88M |
| 2013-09-30 | Not split by product $18.29M 100.00% | $18.29M |
| 2013-06-30 | Not split by product $17.48M 100.00% | $17.48M |
| 2013-03-31 | Not split by product $14.54M 100.00% | $14.54M |
| 2012-12-31 | Not split by product $15.66M 100.00% | $15.66M |
| 2012-09-30 | Not split by product $12.78M 100.00% | $12.78M |
| 2012-06-30 | Not split by product $12.95M 100.00% | $12.95M |
| 2012-03-31 | Not split by product $10.95M 100.00% | $10.95M |
| 2011-12-31 | Not split by product $13.00M 100.00% | $13.00M |
| 2011-09-30 | Not split by product $10.60M 100.00% | $10.60M |
| 2011-06-30 | Not split by product $10.58M 100.00% | $10.58M |
| 2011-03-31 | Not split by product $8.70M 100.00% | $8.70M |
| 2010-12-31 | Not split by product $10.36M 100.00% | $10.36M |
| 2010-09-30 | Not split by product $8.47M 100.00% | $8.47M |
| 2010-06-30 | Not split by product $8.02M 100.00% | $8.02M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |